3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 2
3
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
7
Head & Neck
4
Tumor-Agnostic
3
Thoracic
3
Sarcoma
3
Genitourinary
3
CNS
3
Breast
3
Dermatologic
2
NET
1
Gynecologic
1
Endocrine
1
Conditions
Multiple Endocrine Neoplasia Type 1
96
Pituitary Neoplasms
57
Neuroendocrine Tumors
50
Thyroid Cancer, Papillary
42
Thyroid Neoplasms
16
Obesity
15
Pheochromocytoma
14
Overweight
11
Adrenal Gland Neoplasms
10
Weight Loss
9
Paraganglioma
9
Carcinoma, Neuroendocrine
9
Pancreatic Neoplasms
8
Prostatic Neoplasms
7
Motor Activity
7
Insulinoma
7
Gastrointestinal Neoplasms
7
Brain Neoplasms
7
Adrenocortical Adenoma
7
Acquired Immunodeficiency Syndrome
7
Neoplasm Metastasis
6
Hyperaldosteronism
6
Carcinoma, Medullary
6
Stomach Neoplasms
5
Osteoporosis
5
Neoplasms
5
Meningioma
5
Liver Neoplasms
5
Insulin Resistance
5
HIV Infections
5
Interventions
Poly(ADP-ribose) Polymerase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Neoplasms, Unknown Primary
×
Endocrine
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled